ADC and Bispecific Nanoplatforms
We aim to develop a revolutionary nanotechnology for overcoming current challenges of antibody-drug conjugates and bi- and multispecific antibodies. Nanoparticles can improve design, stability, pharmacokinetic profiles and safety of such platforms, and can be designed to address tumor heterogeneity and immunoregulatory pathways in solid tumors. This will provide a flexible and versatile toolbox for robust and safe antitumor immune response, combining multiple therapeutic concepts for next-generation personalized cancer therapy.
.